鲁马卡托-依伐卡托用于携带苯丙氨酸508缺失（Phe508del）囊性纤维化跨膜传导调节因子（CFTR）纯合突变的囊性纤维化患者 - Suppr

Suppr

超能文献

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

作者信息

Rehman Abdul, Baloch Noor Ul-Ain, Janahi Ibrahim A

出版信息

N Engl J Med. 2015 Oct 29;373(18):1783. doi: 10.1056/NEJMc1510466.

DOI:10.1056/NEJMc1510466

PMID:26510035

Abstract

摘要

相似文献

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.鲁马卡托-依伐卡托用于携带苯丙氨酸508缺失（Phe508del）囊性纤维化跨膜传导调节因子（CFTR）纯合突变的囊性纤维化患者

N Engl J Med. 2015 Oct 29;373(18):1783. doi: 10.1056/NEJMc1510466.

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.针对携带Phe508del CFTR纯合突变的囊性纤维化患者使用鲁马卡托-依伐卡托。

N Engl J Med. 2015 Oct 29;373(18):1783-4. doi: 10.1056/NEJMc1510466.

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.鲁马卡托-依伐卡托用于携带苯丙氨酸508位缺失CFTR基因纯合突变的囊性纤维化患者。

N Engl J Med. 2015 Jul 16;373(3):220-31. doi: 10.1056/NEJMoa1409547. Epub 2015 May 17.

Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.鲁马卡托/依伐卡托联合用药治疗携带Phe508del-CFTR纯合突变的囊性纤维化患者。

Drugs Today (Barc). 2016 Apr;52(4):229-37. doi: 10.1358/dot.2016.52.4.2467205.

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.一种用于治疗携带 phe508del CFTR 突变的囊性纤维化患者的 CFTR 校正剂（芦卡帕替尼）和 CFTR 增强剂（依伐卡托）：一项 2 期随机对照试验。

Lancet Respir Med. 2014 Jul;2(7):527-38. doi: 10.1016/S2213-2600(14)70132-8. Epub 2014 Jun 24.

Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.依库珠单抗/ivacaftor 联合治疗对肺功能亚组纯合子 Phe508del CFTR 囊性纤维化患者的疗效和安全性：一项汇总分析。

Lancet Respir Med. 2016 Aug;4(8):617-626. doi: 10.1016/S2213-2600(16)30121-7. Epub 2016 Jun 10.

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.在 F508del-CFTR 纯合子的 6-11 岁囊性纤维化患者中， lumacaftor 和 ivacaftor 的疗效和安全性：一项随机、安慰剂对照的 3 期临床试验。

Lancet Respir Med. 2017 Jul;5(7):557-567. doi: 10.1016/S2213-2600(17)30215-1. Epub 2017 Jun 9.

Forecasting the Long-Term Clinical and Economic Outcomes of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients with Homozygous phe508del Mutation.预测鲁马卡托/依伐卡托对纯合子Phe508del突变囊性纤维化患者的长期临床和经济结局

Value Health. 2017 Dec;20(10):1329-1335. doi: 10.1016/j.jval.2017.06.014. Epub 2017 Aug 1.

The stony road to phe508del CFTR pharmacotherapy: smoothing the first rock.通往苯丙氨酸508缺失型囊性纤维化跨膜传导调节因子药物治疗的艰难之路：搬开第一块绊脚石

Lancet Respir Med. 2014 Jul;2(7):508-9. doi: 10.1016/S2213-2600(14)70136-5. Epub 2014 Jun 24.

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.评估长期使用组合 Lumacaftor 和 Ivacaftor 疗法治疗囊性纤维化纯合子 F508del-CFTR 突变患者的安全性和疗效（PROGRESS）：一项 3 期扩展研究。

Lancet Respir Med. 2017 Feb;5(2):107-118. doi: 10.1016/S2213-2600(16)30427-1. Epub 2016 Dec 21.

引用本文的文献

Mucosal Immunity in Cystic Fibrosis.囊性纤维化中的黏膜免疫。

J Immunol. 2021 Dec 15;207(12):2901-2912. doi: 10.4049/jimmunol.2100424.

The Distribution and Role of the CFTR Protein in the Intracellular Compartments.囊性纤维化跨膜传导调节蛋白（CFTR）在细胞内区室中的分布及作用

Membranes (Basel). 2021 Oct 22;11(11):804. doi: 10.3390/membranes11110804.

Cost of precision medicine at a referral center for cystic fibrosis.一家囊性纤维化转诊中心的精准医疗成本。

J Bras Pneumol. 2020 Mar 2;46(2):e20190308. doi: 10.36416/1806-3756/e20190308.

Approaching two decades of cystic fibrosis research in Qatar: a historical perspective and future directions.卡塔尔近二十年的囊性纤维化研究：历史回顾与未来方向

Multidiscip Respir Med. 2019 Oct 1;14:29. doi: 10.1186/s40248-019-0193-4. eCollection 2019.

Assessing the Perceptions of Inspiratory Muscle Training in Children With Cystic Fibrosis and Their Multidisciplinary Team: Mixed-Methods Study.评估囊性纤维化患儿及其多学科团队对吸气肌训练的认知：混合方法研究。

JMIR Pediatr Parent. 2018 Oct 25;1(2):e11189. doi: 10.2196/11189.

Residual function of cystic fibrosis mutants predicts response to small molecule CFTR modulators.囊性纤维化突变体的残留功能可预测小分子 CFTR 调节剂的反应。

JCI Insight. 2018 Jul 26;3(14). doi: 10.1172/jci.insight.121159.

Nasospheroids permit measurements of CFTR-dependent fluid transport.类球体允许测量 CFTR 依赖的液体转运。

JCI Insight. 2017 Nov 16;2(22). doi: 10.1172/jci.insight.95734.

Can learning health systems help organisations deliver personalised care?学习型健康系统能否帮助组织提供个性化医疗服务？

BMC Med. 2017 Oct 2;15(1):177. doi: 10.1186/s12916-017-0935-0.

High-Definition Medicine.高清医学

Cell. 2017 Aug 24;170(5):828-843. doi: 10.1016/j.cell.2017.08.007.

DNA Sequence Analysis in Clinical Medicine, Proceeding Cautiously.临床医学中的DNA序列分析：谨慎前行

Front Mol Biosci. 2017 May 3;4:24. doi: 10.3389/fmolb.2017.00024. eCollection 2017.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验